论文部分内容阅读
体外试验从免疫小鼠脾细胞中诱导出对ＦＢＬ－３瘤细胞具有特异性杀伤功能的Ｔ杀伤细胞，转输到同系正常小鼠体内后发现，同时给予肿瘤抗原刺激和７ｄｒＩＬ－２作用，可使受鼠脾细胞获得杀伤ＦＢＬ－３细胞的活性，其杀伤功能与转输的Ｔ杀伤细胞有关。若转输后连续２１ｄ只给予ｒＩＬ－２，不能维持体内建立的杀瘤活性，而间断给予肿瘤抗原再刺激，并联合应用短程ｒＩＬ－２，以１４ｄ为１周期，则可长期维持体内的肿瘤特异性杀伤功能，单独抗原再刺激或单独短程ｒＩＬ－２应用均无此效应。结果表明，过继转输的肿瘤特异性Ｔ杀伤细胞在体内长期存活并保持功能需要肿瘤抗原和ＩＬ－２的共同作用。
In vitro experiments induced T killer cells with specific killing function on FBL-3 tumor cells from spleen cells of immunized mice. After transfusion into homologous normal mice, they were found to give tumor antigen stimulation and 7drIL-2 action. The mouse spleen cells were allowed to kill the activity of FBL-3 cells, and the killing function was related to the transfused T killer cells. If only rIL-2 is given for 21 days after transfusion, the anti-tumor activity established in vivo cannot be maintained, and intermittent administration of tumor antigens for restimulation and combined use of short-range rIL-2 for a period of 14 days can maintain tumors in vivo for a long period of time. Specific killing function, single antigen re-stimulation or short-range rIL-2 alone did not have this effect. The results indicate that tumor-specific T-killer cells that have undergone transfusion have a long-term survival in vivo and that they require a combination of tumor antigen and IL-2 to maintain function.